According to the research report titled ‘Antibody Therapy Market Size By Type (Monoclonal Antibodies [mAbs] {Oncology, Autoimmune Diseases, Infectious Diseases}, Antibody-drug Conjugates [ADCs]), By End-use (Hospitals, Specialty Centers), Industry Analysis Report, Regional Outlook, Growth Potential, COVID-19 Impact Analysis, Price Trends, Competitive Market Share & Forecast, 2022 – 2028’, available with MarketStudyReport, global antibody therapy market is on track to register noteworthy growth over the forecast period 2022-2028.

As per the report findings, factors such as growth in use of monoclonal antibodies (mABs) in COVID-19 patients, prevalence of infectious and chronic diseases, high rate of approval of new therapy in the Europe and EU, growing biologics sector, and surging applications of the treatment are primarily driving global antibody therapy market growth.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4887087/   

Moreover, favorable government policies, and increasing manufacturer focus on investment in R&D activities have been positively swaying the industry dynamics.

Despite the positive outlook, high cost of monoclonal antibody therapeutics, and strict regulatory policies around use of the therapy are restricting the development of this sphere.

Based on product type fragmentation of global antibody therapy market, the antibody-drug conjugates segment captured 3% market share in 2021 and is likely to bolster significantly over the forecast period, primarily due to the growing prevalence of cancer worldwide, and increasing demand for advanced cancer therapy.

Considering the end user scope, the hospitals sub-segment is speculated to record 13.5% CAGR over 2022-2028, owing to developing healthcare infrastructure, growing accessibility in remote areas, and increasing availability of products in hospital settings.

From a regional frame of reference, Latin America market is slated to deliver a CAGR of over 13.1% during the analysis period, triggered by surging financial capability, prevalence of infectious diseases, and growing patient preference for antibody therapies due to their affordability and enhanced outcomes.

Major players in global antibody therapy market are Takeda Pharmaceutical Company Ltd., GlaxoSmithKline plc, Eli Lilly and Co., AstraZeneca plc, Novartis AG, Regeneron Pharmaceuticals Inc., Merck & Co. Inc., Seagen Inc., Johnson & Johnson Services Inc., Bristol-Myers Squibb Co., Amgen Inc., AbbVie Inc., and F. Hoffmann-La Roche AG.